Synergy Pharma (SGYP) Reports Q1 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update
May 10, 2017 4:54 PM EDTReceived FDA Approval of TRULANCE (plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC); Initiated Promotional Efforts for TRULANCE in March 2017 Submitted Supplemental New Drug Application (sNDA) for TRULANCE for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Extended TRULANCE Exclusivity Protection with the Issuance of Three New Patents Highlighted New Data for TRULANCE at Digestive Disease Week (DDW) 2017
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company... More
